• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . The SADDEN DEATH Study: Results from a Pilot Study in Non-ICU COVID-19 Spanish Patients

tetano

Editor, Senior Moderator
J Clin Med


. 2021 Feb 18;10(4):825.
doi: 10.3390/jcm10040825.
The SADDEN DEATH Study: Results from a Pilot Study in Non-ICU COVID-19 Spanish Patients


Carlos Nicol?s P?rez-Garc?a[SUP] 1 [/SUP], Daniel Enr?quez-V?zquez[SUP] 1 [/SUP], Manuel M?ndez-Bail?n[SUP] 2 [/SUP], Carmen Olmos[SUP] 1 [/SUP], Juan Carlos G?mez-Polo[SUP] 1 [/SUP], Rosario Iguar?n[SUP] 1 [/SUP], Noem? Ramos-L?pez[SUP] 2 [/SUP], Jos? Luis Garc?a-Klepzig[SUP] 2 [/SUP], Marcos Ferr?ndez-Escarabajal[SUP] 1 [/SUP], Adri?n Jer?nimo[SUP] 1 [/SUP], Eduardo Mart?nez-G?mez[SUP] 1 [/SUP], Judit Font-Urgelles[SUP] 3 [/SUP], Marcos Fragiel-Saavedra[SUP] 2 [/SUP], Pilar Paz-Arias[SUP] 2 [/SUP], Teresa Romero-Delgado[SUP] 1 [/SUP], Zaira G?mez-?lvarez[SUP] 1 [/SUP], Julia Play?n-Escribano[SUP] 1 [/SUP], Esther Ja?n[SUP] 2 [/SUP], Gianna Vargas[SUP] 4 [/SUP], Elizabeth Gonz?lez[SUP] 4 [/SUP], Eva Orviz[SUP] 2 [/SUP], Irene Burruezo[SUP] 2 [/SUP], Alberto Calvo[SUP] 2 [/SUP], ?ngel Nieto[SUP] 2 [/SUP], ?ngel Molino[SUP] 2 [/SUP], No?l Lorenzo-Villalba[SUP] 5 [/SUP], Emmanuel Andr?s[SUP] 5 [/SUP], Carlos Macaya[SUP] 1 [/SUP], Isidre Vilacosta[SUP] 1 [/SUP]



Affiliations
Free article

Abstract

Introduction: The worldwide pandemic, coronavirus disease 2019 (COVID-19) is a novel infection with serious clinical manifestations, including death. Our aim is to describe the first non-ICU Spanish deceased series with COVID-19, comparing specifically between unexpected and expected deaths. Methods: In this single-centre study, all deceased inpatients with laboratory-confirmed COVID-19 who had died from March 4 to April 16, 2020 were consecutively included. Demographic, clinical, treatment, and laboratory data, were analyzed and compared between groups. Factors associated with unexpected death were identified by multivariable logistic regression methods. Results: In total, 324 deceased patients were included. Median age was 82 years (IQR 76-87); 55.9% males. The most common cardiovascular risk factors were hypertension (78.4%), hyperlipidemia (57.7%), and diabetes (34.3%). Other common comorbidities were chronic kidney disease (40.1%), chronic pulmonary disease (30.3%), active cancer (13%), and immunosuppression (13%). The Confusion, BUN, Respiratory Rate, Systolic BP and age ?65 (CURB-65) score at admission was >2 in 40.7% of patients. During hospitalization, 77.8% of patients received antivirals, 43.3% systemic corticosteroids, and 22.2% full anticoagulation. The rate of bacterial co-infection was 5.5%, and 105 (32.4%) patients had an increased level of troponin I. The median time from initiation of therapy to death was 5 days (IQR 3.0-8.0). In 45 patients (13.9%), the death was exclusively attributed to COVID-19, and in 254 patients (78.4%), both COVID-19 and the clinical status before admission contributed to death. Progressive respiratory failure was the most frequent cause of death (92.0%). Twenty-five patients (7.7%) had an unexpected death. Factors independently associated with unexpected death were male sex, chronic kidney disease, insulin-treated diabetes, and functional independence. Conclusions: This case series provides in-depth characterization of hospitalized non-ICU COVID-19 patients who died in Madrid. Male sex, insulin-treated diabetes, chronic kidney disease, and independency for activities of daily living are predictors of unexpected death.

Keywords: COVID-19; mortality; unexpected death.
 
Back
Top Bottom